Micro-Lab on a Chip Detects Blood Type Within Minutes
|
By LabMedica International staff writers Posted on 27 Jul 2020 |

Image: Schematic diagram of the fully-automatic blood-typing chip exploiting bubbles for quick dilution and detection (Photo courtesy of Tokyo University of Science).
Blood transfusion, if performed promptly, is a potentially life-saving intervention for someone losing a lot of blood. However, blood comes in several types, some of which are incompatible with others. Transfusing an incompatible blood type can severely harm a patient.
There are four major blood types, O, A, B, and AB. These types differ based on the presence or absence of structures called A antigens and B antigens on the surfaces of red blood cells. Blood can be further divided into positive and negative types based on the presence or absence of D antigens on red blood cells. Medical professionals usually tell a patient's blood type with tests involving antibodies against the A and B antigens.
Scientists at the Tokyo University of Science (Tokyo, Japan) developed a fully automated chip that can quickly and reliably determine a patient's blood type. The chip contains a micro-sized "laboratory" with various compartments through which the blood sample travels in sequence and is processed until results are obtained. To start the process, a user simply inserts a small amount of blood, presses a button, and waits for the result. Inside the chip, the blood is first diluted with a saline solution and air bubbles are introduced to promote mixing. The diluted blood is transported to a homogenizer where further mixing, driven by more intensely moving bubbles, yields a uniform solution.
Portions of the homogenized blood solution are introduced into four different detector chambers. Two chambers each contain reagents that can detect either A antigens or B antigens. A third chamber contains reagents that detect D antigens and a fourth chamber contains only saline solution, with no reagent, and serves as a negative control chamber in which the user should not observe any results. Antigen-antibody reaction will cause blood to agglutinate, and by looking at which chambers have hemagglutination, the user can tell the blood type and whether the blood is positive or negative. The team screened blood samples from 10 donors and obtained accurate results for all 10 samples. The time needed to determine a single sample's blood type was only five minutes.
Masahiro Motosuke, PhD, an associate professor and co-author of the study, said, “The advancement of simple and quick blood test chip technologies will lead to the simplification of medical care in emergency situations and will greatly reduce costs and the necessary labor on parts of medical staff.” The study was originally published online on April 14, 2020 in the journal Biomicrofluidics.
Related Links:
Tokyo University of Science
There are four major blood types, O, A, B, and AB. These types differ based on the presence or absence of structures called A antigens and B antigens on the surfaces of red blood cells. Blood can be further divided into positive and negative types based on the presence or absence of D antigens on red blood cells. Medical professionals usually tell a patient's blood type with tests involving antibodies against the A and B antigens.
Scientists at the Tokyo University of Science (Tokyo, Japan) developed a fully automated chip that can quickly and reliably determine a patient's blood type. The chip contains a micro-sized "laboratory" with various compartments through which the blood sample travels in sequence and is processed until results are obtained. To start the process, a user simply inserts a small amount of blood, presses a button, and waits for the result. Inside the chip, the blood is first diluted with a saline solution and air bubbles are introduced to promote mixing. The diluted blood is transported to a homogenizer where further mixing, driven by more intensely moving bubbles, yields a uniform solution.
Portions of the homogenized blood solution are introduced into four different detector chambers. Two chambers each contain reagents that can detect either A antigens or B antigens. A third chamber contains reagents that detect D antigens and a fourth chamber contains only saline solution, with no reagent, and serves as a negative control chamber in which the user should not observe any results. Antigen-antibody reaction will cause blood to agglutinate, and by looking at which chambers have hemagglutination, the user can tell the blood type and whether the blood is positive or negative. The team screened blood samples from 10 donors and obtained accurate results for all 10 samples. The time needed to determine a single sample's blood type was only five minutes.
Masahiro Motosuke, PhD, an associate professor and co-author of the study, said, “The advancement of simple and quick blood test chip technologies will lead to the simplification of medical care in emergency situations and will greatly reduce costs and the necessary labor on parts of medical staff.” The study was originally published online on April 14, 2020 in the journal Biomicrofluidics.
Related Links:
Tokyo University of Science
Latest Hematology News
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more




.jpg)


